Cargando…
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
BACKGROUND AND AIM: Oral bisphosphonates have been shown to reduce the risk of fractures in patients with osteoporosis. It can be assumed that the clinical effectiveness of oral bisphosphonates depends on persistence with therapy. METHODS: The influence of persistence with and adherence to oral bisp...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778431/ https://www.ncbi.nlm.nih.gov/pubmed/19936142 |
_version_ | 1782174246074580992 |
---|---|
author | Höer, Ariane Seidlitz, Cornelia Gothe, Holger Schiffhorst, Guido Olson, Melvin Hadji, Peyman Häussler, Bertram |
author_facet | Höer, Ariane Seidlitz, Cornelia Gothe, Holger Schiffhorst, Guido Olson, Melvin Hadji, Peyman Häussler, Bertram |
author_sort | Höer, Ariane |
collection | PubMed |
description | BACKGROUND AND AIM: Oral bisphosphonates have been shown to reduce the risk of fractures in patients with osteoporosis. It can be assumed that the clinical effectiveness of oral bisphosphonates depends on persistence with therapy. METHODS: The influence of persistence with and adherence to oral bisphosphonates on fracture risk in a real-life setting was investigated. Data from 4451 patients with a defined index prescription of bisphosphonates were included. Fracture rates within 180, 360, and 720 days after index prescription were compared between persistent and non-persistent patients. In an extended Cox regression model applying multiple event analysis, the influence of adherence was analyzed. Persistence was defined as the duration of continuous therapy; adherence was measured in terms of the medication possession ratio (MPR). RESULTS: In patients with a fracture before index prescription, fracture rates were reduced by 29% (p = 0.025) comparing persistent and non-persistent patients within 180 days after the index prescription and by 45% (p < 0.001) within 360 days. The extended Cox regression model showed that good adherence (MPR ≥ 0.8) reduced fracture risk by about 39% (HR 0.61, 95% CI 0.47–0.78; p < 0.01). CONCLUSIONS: In patients with osteoporosis-related fractures, good persistence and adherence to oral bisphosphonates reduced fracture risk significantly. |
format | Text |
id | pubmed-2778431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27784312009-11-23 Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis Höer, Ariane Seidlitz, Cornelia Gothe, Holger Schiffhorst, Guido Olson, Melvin Hadji, Peyman Häussler, Bertram Patient Prefer Adherence Original Research BACKGROUND AND AIM: Oral bisphosphonates have been shown to reduce the risk of fractures in patients with osteoporosis. It can be assumed that the clinical effectiveness of oral bisphosphonates depends on persistence with therapy. METHODS: The influence of persistence with and adherence to oral bisphosphonates on fracture risk in a real-life setting was investigated. Data from 4451 patients with a defined index prescription of bisphosphonates were included. Fracture rates within 180, 360, and 720 days after index prescription were compared between persistent and non-persistent patients. In an extended Cox regression model applying multiple event analysis, the influence of adherence was analyzed. Persistence was defined as the duration of continuous therapy; adherence was measured in terms of the medication possession ratio (MPR). RESULTS: In patients with a fracture before index prescription, fracture rates were reduced by 29% (p = 0.025) comparing persistent and non-persistent patients within 180 days after the index prescription and by 45% (p < 0.001) within 360 days. The extended Cox regression model showed that good adherence (MPR ≥ 0.8) reduced fracture risk by about 39% (HR 0.61, 95% CI 0.47–0.78; p < 0.01). CONCLUSIONS: In patients with osteoporosis-related fractures, good persistence and adherence to oral bisphosphonates reduced fracture risk significantly. Dove Medical Press 2009-11-03 /pmc/articles/PMC2778431/ /pubmed/19936142 Text en © 2009 Höer et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Höer, Ariane Seidlitz, Cornelia Gothe, Holger Schiffhorst, Guido Olson, Melvin Hadji, Peyman Häussler, Bertram Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title | Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title_full | Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title_fullStr | Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title_full_unstemmed | Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title_short | Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
title_sort | influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778431/ https://www.ncbi.nlm.nih.gov/pubmed/19936142 |
work_keys_str_mv | AT hoerariane influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT seidlitzcornelia influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT gotheholger influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT schiffhorstguido influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT olsonmelvin influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT hadjipeyman influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis AT hausslerbertram influenceonpersistenceandadherencewithoralbisphosphonatesonfractureratesinosteoporosis |